人源化抗Her2单抗对BT474人乳腺癌细胞的抗癌效应研究

Anti-cancer Effect of Humanized Anti-Her2 Monoclonal Antibody on BT474 Human Breast Cancer Cells

目的评价人源化抗Her2单抗(MIL41)注射液体内外对人乳腺癌细胞BT474的抗癌效应。方法流式细胞仪分析人乳腺癌BT474细胞的Her2表达量;采用CCK-8法测定MIL41体外对BT474细胞的增殖抑制效应;用裸鼠皮下移植瘤模型法,评价MIL41的体内抗癌作用。结果流式细胞仪显示BT474细胞为Her2高表达的细胞系;体外实验显示,MIL41对受试细胞的增殖具有良好的抑制作用;体内实验表明,MIL41对裸鼠皮下移植瘤生长具有较强的抑制作用,呈现良好的量效关系,在给药剂量为12mg·kg-1时,瘤重抑制率达到56.3%(P<0.05)。结论人源化抗Her2单抗体内外对人乳腺癌细胞BT474具有良好的抑制作用。

Objective To evaluate the anti-cancer effect of humanized anti-Her2 monoclonal antibody（MIL41）injection on human breast cancer cell line BT474 in vitroandin vivo.Methods Her2 expression in human breast cancer cell BT474 was analyzed by flow cytometry.The inhibitory effect of MIL41 on proliferation of BT474 cells was evaluated using CCK-8 method.The subcutaneous transplantation tumor model of nude mice was adopted to evaluate the anti-cancer effect of MIL41 in vivo.Results Flow cytometry showed that BT474 cells were highly-expressed Her2 cell lines.MIL41 was effective in inhibiting the proliferation of the cells in vitro.The result in vivo experiments showed that the growth of transplanted tumor in nude mice was well inhibited in a dose-ependent manner.When the dosage was 12 mg·kg-1,the inhibition rate of tumor weight was 56.3%（P〈0.05）.Conclusion Humanized anti-Her2 monoclonal antibody has a significant inhibitory effect on human breast cancer cell BT474 in vitro andin vivo.